IntoCell, Inc. (KOSDAQ:287840)
South Korea · Delayed Price · Currency is KRW 23,900
-500 (-2.05%)
At close: Aug 5, 2025, 3:30 PM KST
Theseus Pharmaceuticals Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
Net Income | -8,950 | -9,913 | -16,775 | -8,667 | -7,331 | -9,789 | Upgrade |
Depreciation & Amortization | 667.74 | 684.79 | 842.83 | 776.07 | 646.08 | 561.51 | Upgrade |
Asset Writedown & Restructuring Costs | - | - | 31.58 | - | - | - | Upgrade |
Loss (Gain) From Sale of Investments | 15.32 | -12.84 | -63.46 | 17.33 | -11.67 | - | Upgrade |
Stock-Based Compensation | 24.95 | 50.43 | 134.4 | 199.47 | 255.83 | 264.23 | Upgrade |
Other Operating Activities | 438.6 | 368.69 | 415.99 | 179.59 | 2,775 | 5,601 | Upgrade |
Change in Accounts Receivable | - | -7.1 | -5.94 | - | - | - | Upgrade |
Change in Other Net Operating Assets | 602.99 | 1,783 | -1,354 | 1,431 | -62.35 | -1,326 | Upgrade |
Operating Cash Flow | -7,200 | -7,046 | -16,774 | -6,063 | -3,728 | -4,688 | Upgrade |
Capital Expenditures | -90.92 | -71.28 | -233.75 | -373.13 | -439.54 | -384.47 | Upgrade |
Sale (Purchase) of Intangibles | -1,384 | -1,166 | -838.01 | -430.42 | -581.68 | -458.48 | Upgrade |
Investment in Securities | 3,007 | 5,074 | 9,857 | 9,102 | -24,943 | 3,069 | Upgrade |
Other Investing Activities | 20.67 | -146.42 | 65 | -140 | -1,001 | -202.58 | Upgrade |
Investing Cash Flow | 1,553 | 3,690 | 8,850 | 8,158 | -26,966 | 2,023 | Upgrade |
Short-Term Debt Issued | - | - | 10,000 | - | 5,000 | - | Upgrade |
Total Debt Issued | - | - | 10,000 | - | 5,000 | - | Upgrade |
Short-Term Debt Repaid | - | - | - | -5,000 | - | - | Upgrade |
Long-Term Debt Repaid | - | -21.93 | -23.97 | -25.87 | -3,026 | -23.35 | Upgrade |
Total Debt Repaid | -21.76 | -21.93 | -23.97 | -5,026 | -3,026 | -23.35 | Upgrade |
Net Debt Issued (Repaid) | -21.76 | -21.93 | 9,976 | -5,026 | 1,974 | -23.35 | Upgrade |
Issuance of Common Stock | 4,228 | 4,228 | 107.35 | 50.8 | - | 34,030 | Upgrade |
Other Financing Activities | -0 | 150 | -0 | - | -0 | - | Upgrade |
Financing Cash Flow | 4,207 | 4,356 | 10,083 | -4,975 | 1,974 | 34,007 | Upgrade |
Foreign Exchange Rate Adjustments | 2.01 | 11.56 | 14.4 | -0.01 | 0.29 | -0.01 | Upgrade |
Miscellaneous Cash Flow Adjustments | 0 | - | - | - | - | - | Upgrade |
Net Cash Flow | -1,439 | 1,012 | 2,175 | -2,880 | -28,720 | 31,342 | Upgrade |
Free Cash Flow | -7,291 | -7,117 | -17,007 | -6,436 | -4,168 | -5,072 | Upgrade |
Free Cash Flow Margin | -247.37% | -244.99% | -1052.17% | - | -2976.28% | - | Upgrade |
Free Cash Flow Per Share | -553.37 | -542.77 | -1310.88 | -496.10 | -371.79 | -842.03 | Upgrade |
Cash Interest Paid | 258.91 | 308.37 | 168.12 | 2.68 | 55.05 | 57 | Upgrade |
Cash Income Tax Paid | - | -35.19 | -15.89 | 101.12 | 5.44 | 1.5 | Upgrade |
Levered Free Cash Flow | - | -4,858 | -12,345 | -4,391 | -32,954 | -1,441 | Upgrade |
Unlevered Free Cash Flow | - | -4,661 | -12,307 | -4,389 | -32,532 | -475.18 | Upgrade |
Change in Net Working Capital | - | -2,011 | 1,209 | -1,537 | 29,008 | -2,676 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.